UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
 
January 2017
 
Commission file number: 001-36288
 
Akari Therapeutics, Plc
(Translation of registrant's name into English)
 
24 West 40th Street, 8th Floor
New York, NY 10018
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F  x       Form 40-F ¨
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 
CONTENTS
 
Akari Therapeutics, Plc (the “Company”) has posted to its website a corporate presentation. A copy of the presentation is furnished with this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 and is incorporated herein by reference.
 
The information contained in this report (including the exhibit hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form S-3, File No. 333-207443.
 
Cautionary Note Regarding Forward-Looking Statements
 
The presentation attached hereto as Exhibit 99.1 may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: an inability or delay in obtaining required regulatory approvals for Coversin and any other product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for Coversin and any other product candidates and unexpected costs that may result therefrom; failure to realize any value of Coversin and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for Coversin may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; our inability to obtain additional capital on acceptable terms, or at all; unexpected cost increases and pricing pressures; uncertainties of cash flows and inability to meet working capital needs; and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K filed on March 23, 2016. Except as otherwise noted, these forward-looking statements speak only as of the date of the presentation and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this presentation. We caution investors not to place considerable reliance on the forward-looking statements contained in this presentation. 
 
Exhibit No.
 
 	99.1	Investor Presentation of Akari Therapeutics, Plc dated January 2017.	

 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 	Akari Therapeutics, Plc	 	
 	(Registrant)	 	
 	 	 	 	
 	By:	/s/ Robert M. Shaw	 	
 	Name:  	Robert M. Shaw	 	
 	General Counsel & Secretary	 	
       
Date: January 9, 2017

 

Exhibit 99.1

January 2017 NASDAQ: AKTX

 

Cautionary Note Regarding Forward - Looking Statements Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27A of the Securit ies Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "es timates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We int end these forward - looking statements to be covered by the safe harbor provisions for forward - looking statements contained in Section 27A of the Se curities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor pro vis ions. These forward - looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expect ati ons, strategies and prospects as reflected in or suggested by those forward - looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from t hos e described in the forward - looking statements and will be affected by a variety of risks and factors that are beyond our control. Risks and uncert ainties for our company include, but are not limited to: an inability or delay in obtaining required regulatory approvals for Coversin and an y o ther product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in ob taining successful clinical results for Coversin and any other product candidates and unexpected costs that may result therefrom; failure to rea liz e any value of Coversin and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing products; the approva l b y the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks res ult ing from unforeseen side effects; risk that the market for Coversin or other product candidates may not be as large as expected; inabi lit y to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial sc ale manufacturing capabilities; unexpected cost increases and pricing pressures; and uncertainty of our ability to raise capital and our inability to meet working capital needs. Many of these factors that will determine actual results are beyond our ability to control or pre dic t. For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, p erf ormance or achievements expressed or implied in such forward - looking statements, see the “Risk Factors” section of our most recently filed 10K. Existing and prospective investors are cautioned not to place undue reliance on these forward - looking statements, which speak only as of the date hereof. The statements made in this press release speak only as of the date stated herein, and subsequent events and developments may cau se our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we unde rta ke any obligation, to update or revise any forward - looking statements contained in this news release to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward - looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by l aw. Copyright Akari Therapeutics, Plc 2017 1

 

Portfolio of Anti - Inflammatory Compounds for Orphan Conditions Advancing Clinical Program Coversin Competitive Advantages • PNH resistant patient successfully on therapy for >11 months • PNH - expect Ph2 data 1Q 2017 & Ph3 initiated mid - 2017 • aHUS pivotal trial expected 2017 • Complete ablation with once - daily dosing • Market research indicates sizeable patient sub Q preference • Weekly dosing in development – Phase 1 expected 1Q 2018 • LTB4 inhibition may reduce thrombotic risk Portfolio Covering Multiple Pathways • Complement - engineered for tissue targeting and longer T1/2 • Eicosanoid - LTB4 - only; preclinical completed by YE 2017 • Bioamine - targeted for clinic early 2018 • Dual action C5+LTB4 - targeted for clinic by YE 2017 Exploiting power of nature: Ticks evolved wide range of immunomodulators over 300 million years Copyright Akari Therapeutics, Plc 2017 2

 

Pipeline of Diverse Molecules Targeting Multiple Pathways Tissue Targeted (NMJ) Complement System Coversin™ Coversin LA™ Oral Eicosanoid System Bioamine System LTB4 LTB4 LA Histamine binding Serotonin binding Thromboxane binding Lipoxin binding Phase 2 Phase 1 Preclinical Discovery LTB4 + C5 Copyright Akari Therapeutics, Plc 2017 3

 

Phase 1 Phase 3 2018 2017 Phase 2/3 Phase 3 Ongoing treatment/potential regulatory pathway Phase 3 Preclinical Phase 2 Phase 2 Current Coversin Clinical Timeline Eculizumab Resistance PNH aHUS GBS Coversin LA Phase 2 Copyright Akari Therapeutics, Plc 2017 4 Filing 2019

 

C5a, LTB4 and MAC act jointly on granulocytes, leukocytes and many other immune and tissue cell types - potentially causing inflammation and damage Coversin Differentiated by Dual C5 and LTB4 Action MAC PLA2 Arachidonic acid C3 C3b Classical Mannose binding lectin Alternative Activation pathways C3 convertase Opsonisation Amplification loop Liver, Macrophages, etc. C5 convertase C3a C5b C6 C7 C9 C8 C5 Inflammation autoimmunity C3b Anaphylatoxins Lysis and cell death C5a LTB4 Lipoxygenases Ig binding to Fc gamma receptors Cytokines e.g. TNF and IL8 LTA4 Toll - like receptors Coversin Coversin 0 25 50 75 100 * * LTB4 % after treatment* Albumin E. coli Eculizumab * In vivo E coli model, Barrett - Due et al 2011 Copyright Akari Therapeutics, Plc 2017 5 • Eculizumab only inhibits human C5 • C5 and LTB4 act synergistically

 

Phase Ib Trial: Once Daily Dosing Provides Full Ablation • Subjects received 4 ablating injections Q12 for 2 days, then QD for 5 days • Dose effect demonstrates once - daily dosing • Advanced 30 mg dose into Ph2 trial • Alignment of Elisa and Lytic CH50 results 0 20 40 60 80 100 120 140 1 7 13 19 25 31 37 43 49 55 61 67 73 79 85 91 97 103 109 115 121 127 133 139 145 151 157 163 169 175 181 187 193 CH50 U Eq/L Placebo Low (15 mg) High (30 mg) Medium (22.5 mg) Time from first dose (h) 0 30 60 90 120 0 24 48 72 96 120 144 168 192 Elisa U Eq /ml Lytic 0 30 60 90 120 0 24 48 72 96 120 144 168 192 Placebo Last dose Placebo Cohort 1 (30 mg) Cohort 2 (22.5 mg) Cohort 1 (30 mg) Cohort 2 (22.5 mg) CH50 CH50 Last dose Copyright Akari Therapeutics, Plc 2017 6

 

>11 Months Successful Treatment* of Eculizumab - Resistant PNH Patient • Since day 18: ‒ No dose changes ‒ No haemolytic episodes; no SAEs ‒ CH50 <8.0 U Eq /mL (lower limit of quantification) * Pursuant to an approved clinical protocol in the Netherlands 2016 EH, Saskia Langemeijier, University of Radboud, Nijmegen Weeks Coversin started 0 20 40 60 80 100 120 140 0 200 400 600 800 1,000 1,200 1,400 LDH (IU/ml) 1.5 ULN Initial dose finding for first treated patient 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 0 34 36 38 CH50 CH50 LHD 40 42 44 46 Copyright Akari Therapeutics, Plc 2017 7

 

Eculizumab - Resistant PNH Patient: No Neutralizing Antibodies to Date Coversin 0 20 40 60 80 100 120 PNS Anti-Cov Rb Day 0 Day 16 Day 34 Day 58 Day 83 Day 125 Day 153 Day 181 Day 205 Day 237 Anti-Cov Rb % inhibition of lysis + ve * CTR 14 17 21 9 kDa Days since first dose + ve * CTR Coversin * Positive control (+ ve CTR) rabbit anti - Coversin serum used at 1:8000 dilution, all patient serum samples used at 1:200 dilution 0 16 237 34 58 83 125 153 205 181 • Antibody first detectable after 2 weeks • Response peaked at 9 weeks, then declined to stable level • Antibody is low titre undetectable by ELISA • Purified IgG antibody is non - neutralizing Copyright Akari Therapeutics, Plc 2017 8

 

PNH Clinical Program Phase 3 Planned for Mid - 2017 • Trial initiation planned mid - 2017 • Network of leading PNH centers • Scientific advice received from EMA & FDA • Infrastructure in place to roll over from Phase 2 - 3 Phase 2 Ongoing Phase 3 2017 • Data release expected March 2017 • Leading PNH treatment centers in EU • Primary efficacy endpoint: LDH at 28 days • Secondary efficacy endpoints: Hgb, transfusions, hemoglobinuria, CH50, LDH, and quality of life Copyright Akari Therapeutics, Plc 2017 9

 

aHUS and GBS Clinical Programs • Open label Phase 2 first patient expected 2Q 2017 • Leading treatment centers in EU • Planned to progress directly into Ph 3 trial in late 2017 aHUS • Immune - mediated polyneuropathy with severe clinical outcomes (2 – 12% die; 10 – 35% permanent impairment) • Phase 2 trial focused on Americas and Zika - induced GBS • 28 days dosing + 6 month follow up GBS Copyright Akari Therapeutics, Plc 2017 10

 

Pipeline of tick - derived molecules selected to suppress mediators of chronic inflammation in wide range of orphan disorders Exploiting the Power of Nature: Akari Discovery Platform Coversin engineered molecules targeted to complement pathway New Akari tick - derived anti - inflammatory molecules • Extended half - life (LA) • Tissue targeting • Dual action C5+LTB4 • Eicosanoid pathway (LTB4) • Bioamine pathway (Histamine) • Other complement pathway targets Copyright Akari Therapeutics, Plc 2017 11

 

Once - Weekly Formulation Coversin LA • Addition of 600 Pro - Ala - Ser amino acids (PASylation ™ ) • Increases MW from 17 to 68 kDa – Apparent ~600 kDa MW • Terminal half life est. at 4 days • Phase 1 clinical study - expected timing 4Q 2017 • Clean initial toxicology comparable to unmodified Coversin Evidence to date supports projection of weekly dosing regime in humans PAS Coversin Coversin 5% Human PK Simulation Free C5 Following Single Dose Copyright Akari Therapeutics, Plc 2017 12 * PASylation trademark and technology owned by XL - protein GmbH

 

Tissue - Targeting Coversin Program to Access New Indications • Coversin targeted to specific tissues by fusing peptides to N - terminal • First condition is Myasthenia Gravis (MG) – Neuromuscular junction (NMJ) using targeted aptamer – Dose expected to be <20% of that for other C5 indications – Potential benefits: ▪ Reduced infection risk ▪ Lower cost of treatment; opens up larger patient population ▪ Improved efficacy – Phase 1 trials – expected by mid - 2018 Copyright Akari Therapeutics, Plc 2017 13

 

Coversin - Dual C5/LTB4 Activity May Lead to New Market Opportunities • Synergistic with C5 inhibition • Co - occurrence at inflammatory site • Feedback loops between C5 and LTB4 • Can also be activated independently • Lung - Obliterative Bronchiolitis • Juvenile Rheumatoid Arthritis • Ophthalmic – Sjogren’s • Blistering skin – Severe Pemphigoid Copyright Akari Therapeutics, Plc 2017 14 First Phase 2 trial initiation expected 2H 2017 Competitive Advantages Potential Indications

 

LTB4 Inhibitors: Increasingly Important Clinical Target • Differentiated MOA • Captures ligand • No effect on cysLT or lipoxines , resolvins • Does not cause shunt to prostanoids • Leaves LTA4H hydrolytic activity against PGP intact • Lung: ‒ Treatment resistant Asthma ‒ Alpha - 1 - Antitrypsin ‒ COPD (freq. exacerbation) ‒ Pulmonary Hypertension • Oncology: ‒ Checkpoint combination therapy Copyright Akari Therapeutics, Plc 2017 15 Competitive Advantages Potential Indications Expected preclinical completion 2017 + first - in - man in 2018

 

L - Coversin Competitive Advantage: Unique Mode of Action Ig binding to Fc gamma receptors Cytokines e.g. TNF and IL8 Toll - like receptors Arachidonic acid LTB4 Lipoxygenases (5 - LOX) LTA4 Coversin PGP inactivated PGP Anaphylatoxin C5a PLA2 Collagen Matrix Metalloproteases BLT1 BLT2R Ono/JJ zileuton/Mariposa Lipoxins Eiger / Celltaxys / Naegis PROINFLAMMATORY ANTI - INFLAMMATORY PROINFLAMMATORY Copyright Akari Therapeutics, Plc 2017 16

 

Portfolio of Distinct Bioamine Inhibitors • Different molecules targeting different or multiple ligands • Prevents interaction with all four GPCRs (H1, H2, H3, H4) • Mast cell stabilizer • Skin - severe eczema • CNS - neuropathic pain • Ophthalmic - retinopathies Copyright Akari Therapeutics, Plc 2017 17 Competitive Advantages Potential Indications Expected preclinical completion 2017 + first - in - man in 2018

 

Financial Summary • $75 million PIPE September 2015 • ADS outstanding 11,776,934 • ADS Fully Diluted 12,667,441 • Cash as of Sept 30 $51m (no debt) • Funding through Early 2018 Copyright Akari Therapeutics, Plc 2017 18

 

Executive Chairman • Lead investor (RPC); founder Akari; medical entrepreneur Chief Executive Officer • Celsus; Venrock; Piper Jaffray; Internist Chief Operating Officer • LEK Consulting; Head of Research - Investec; RPC Medical Director • European Medical Director, BMS; 25 years development experience Chief Scientific Officer • Coversin inventor; 15 years biotech development from parasites Head Clinical Development • Takeda; Shire; Schering - Plough; Solvay Vice President of Worldwide Regulatory Affairs • Biopure ; Millennium; Archemix ; ARIAD; Tarsa ; Actelion Chief Financial Officer • Lev Pharmaceuticals; EpiCept; Synvista; Tetragenix General Counsel • KV Pharmaceuticals; Savient Pharmaceuticals; Pliva Inc. Corporate Development • Aprecia Pharmaceuticals; McKinsey Consulting; Sandoz GmbH Proven Management Team Ray Prudo MD Gur Roshwalb MD, MBA Clive Richardson Dov Elefant Robert Shaw JD Wynne Weston - Davies, MD Miles Nunn PhD Michael King MBA Copyright Akari Therapeutics, Plc 2017 19 Brihad Abhyankar FRCS Nigel Hernandez PhD

 

Milestones Historic and Anticipated 2016 2H 2017 1H 2017 • Phase 1b • PNH resistant patient treated (>11 months) • Phase 2 PNH trial initiated • US IND and US/EU orphan designations allowed • CMC scale up 4Q 2016 • Phase 2 PNH data – 1Q 2017 • Phase 2 GBS trial – initiation • Phase 2 aHUS trial – initiation • Animal POC for eicosanoid and bioamine pathways • Phase 3 PNH trial – initiation • Phase 3 aHUS trial – initiation • Phase 1 Coversin LA trial – initiation • Phase 2 dual action C5 + LTB4 – initiation Copyright Akari Therapeutics, Plc 2017 20

 

Appendix Copyright Akari Therapeutics, Plc 2017 21

 

Dual C5/LTB4 Activity May Lead To New Market Opportunities Roversi P et al. J Biol Chem 288: 18789; 2013 Immune - Complex Mediated Acute Lung Injury Mouse Model * Proteins only ** LTB 4 (0:1, outer) or ethanol (0:0, central) only 4 : 1 2 : 1 1 : 1 4 : 0 * 0.5 : 1 + ve and – ve controls** Molar ratio protein:LTB4 Ovalbumin Coversin Anti - C5 C oversin Blocks Effects of LTB4 on Human Skin Copyright Akari Therapeutics, Plc 2017 22 Complete Inhibition

 

• Coversin linked to peptide which binds laminin γ1 ‒ Differentially concentrates at basal lamina of NMJ • Immunohistochemical analysis in mice shows that Coversin - laminin construct – unlike Coversin alone - concentrates to NMJ of diaphragm and tibialis muscles Coversin Tissue Targeting: NMJ • No evidence of weakness by standard behavioral testing Copyright Akari Therapeutics, Plc 2017 23

 

n=5 n=5 n=10 n=10 n=10 • Neutrophilic response (mean and SEM) in bronchoalveolar lavage fluid of mice 8 hr following 50µg LPS i.t. • Treatments (i.t.): 100 µg Coversin, 100 µg LTB4 saturated Coversin, 50 mg/Kg Zileuton or vehicle • Statistical comparisons to vehicle and between Coversin and Zileuton made using a one - way ANOVA, followed by a Dunnett’s test, * P<0.01 and # P<0.05. Comparisons to the vehicle (*) and between Coversin (#) and Zileuton * # * * LPS Mouse Lung Challenge Model Note: saturated Coversin inhibits C5 only, Coversin inhibits C5 and LTB 4 Copyright Akari Therapeutics, Plc 2017 24 Demonstrates superior neutrophil inhibition with Coversin vs treatment with Zileuton

 

January 2017 NASDAQ: AKTX